Nivolumab led to a greater proportion of patients achieving an objective response and fewer toxic effects than with alternative available chemotherapy regimens for patients with advanced melanoma that has progressed after ipilimumab, or ipilimumab and a BRAF inhibitor if they were BRAF V600 mutation-positive. This evidence concerns the gene BRAF and melanoma.